CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'

GLP-1Negative
AI Analysis

Summary

Citi analyst flags a slowdown in GLP-1 prescription growth at Novo Nordisk and reiterates a 'sell' rating on the stock, raising concerns about demand trajectory for the company's GLP-1 products.

Importance:5/10
Sentiment:
-0.70
GLP-1prescription_slowdownanalyst_downgrademarket_concern
Related Companies

Read the original article

Published by yahoo_finance on September 2, 2026 2:30 PM

Read Original